The addition of pembrolizumab to preoperative radiotherapy (RT) improved disease-free survival (DFS) for patients with stage III undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS) in the randomized SU2C-SARC032 trial. To precisely identify patients who benefit from pembrolizumab and RT, we performed comprehensive multi-omics profiling of pre- and post-treatment tumor and blood samples, including bulk RNA-seq, flow cytometry, and cytometry…
Distinct Sarcoma Microenvironments Predict Benefit from Addition of Pembrolizumab to Preoperative Radiotherapy and Surgery in SU2C-SARC032
medRxiv Oncology | | Testa, S., Himes, J. E., Subramanian, A., Nouth, S. C. L., Ballman, K. V., Heise, R. S., Pierpoint, M., Nemat-Gorgani, N., Sears, T. J., Binkley, M. S., Kalbasi, A., Corcoran, D. L., Hong, A. M., Brigman, B. E., Riedel, R. F., van de Rijn, M., Mowery, Y. M., Weinhold, K. J., Kirsch, D. G., Moding, E. J.
Topics: sarcoma, immunotherapy, radiation, clinical-trials